BeiGene Closes on Property for New U.S. Manufacturing and Scientific R&D Middle

BeiGene plans to develop 42-acre website at Princeton West Innovation Park in Hopewell, New Jersey as a producing website for superior new medicines

HOPEWELL, N.J. & CAMBRIDGE, Mass. & BEIJING, November 23, 2021–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a worldwide biotechnology firm centered on growing and commercializing progressive most cancers medicines worldwide, introduced right now that it has bought a 42-acre website on the Princeton West Innovation Campus in Hopewell, N.J. to deal with a brand new state-of-the-art manufacturing campus and scientific R&D middle. As a key a part of BeiGene’s continued progress, the corporate is investing in U.S. manufacturing to additional increase and diversify its world provide chain and construct new manufacturing capabilities for its deep pipeline of biologic and drug candidates.

This press launch options multimedia. View the complete launch right here:

Rendering of BeiGene’s deliberate state-of-the-art manufacturing campus and scientific R&D middle on its new 42-acre website on the Princeton West Innovation Campus in Hopewell, N.J. Credit score: BeiGene

Topic to finalizing the event plans, BeiGene expects to take a position a number of hundred million {dollars} within the preliminary section of building, along with the acquisition of the property, for the state-of-the-art facility that’s anticipated to incorporate as much as roughly 400,000 sq. toes of devoted commercial-stage biologic pharmaceutical manufacturing, together with as much as 16,000 liters of biologics capability, together with scientific R&D and workplace area. Development of the preliminary section is predicted to start in 2022 and be accomplished in late-2023 or in 2024. As well as, the property has a couple of million sq. toes of developable actual property for potential future growth.

“With this property acquisition, we plan to determine a flagship manufacturing and scientific R&D middle within the U.S. to diversify our world provide chain. We’re proud to take this subsequent step in our journey to advance impactful remedies and make them extra accessible to sufferers around the globe,” stated John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene. “We’ve already begun hiring extra colleagues from the deep expertise pool in New Jersey and sit up for serving as a member of the thriving Princeton-Hopewell enterprise neighborhood.”

“We’re extraordinarily excited that BeiGene has taken the subsequent step within the firm’s push to fabricate progressive most cancers medicines proper right here in New Jersey,” stated Governor Phil Murphy. “Our objective since day one has been to create an surroundings in New Jersey that fosters the expansion of firms like BeiGene and we’re excited to see what’s subsequent as the corporate expands.”

“With extra new firms, like BeiGene, coming into the Princeton West Innovation Campus, Hopewell Township’s future as a frontrunner within the biotech base continues to come back to fruition. BeiGene’s experience in growing progressive most cancers remedies mixed with their deliberate state-of-the-art facility makes this a win-win-win for Hopewell, BeiGene, and the thousands and thousands of most cancers sufferers whose lives will hopefully enhance from BeiGene medicines. We’re proud that these medicines can be manufactured proper right here,” stated Hopewell Township Mayor Julie Blake.

BeiGene acquired the Hopewell property from Lincoln Equities Group and has retained DPR Development as its building administration agency and IPS as its architectural and engineering agency.

About BeiGene

BeiGene is a worldwide, science-driven biotechnology firm centered on growing progressive and inexpensive medicines to enhance remedy outcomes and entry for sufferers worldwide. With a broad portfolio of greater than 40 scientific candidates, we’re expediting improvement of our various pipeline of novel therapeutics by our personal capabilities and collaborations. We’re dedicated to radically bettering entry to medicines for 2 billion extra folks by 2030. BeiGene has a rising world group of over 7,700 colleagues throughout 5 continents. To be taught extra about BeiGene, please go to and observe us on Twitter at @BeiGeneGlobal.

Ahead-Trying Statements

This press launch comprises forward-looking statements throughout the that means of the Personal Securities Litigation Reform Act of 1995 and different federal securities legal guidelines, together with statements concerning BeiGene’s plans and expectations to determine a brand new manufacturing and scientific R&D middle in New Jersey, to fabricate commercial-stage medicines and drug candidates on the website and to diversify its world provide chain, the anticipated timing for the initiation and completion of building, BeiGene’s anticipated funding in and recruiting of expertise for the brand new manufacturing and R&D middle, and BeiGene’s plans, commitments, aspirations and objectives below the heading “About BeiGene”. Precise outcomes could differ materially from these indicated within the forward-looking statements on account of numerous essential elements, together with BeiGene’s skill to display the efficacy and security of its drug candidates; the scientific outcomes for its drug candidates, which can not help additional improvement or advertising and marketing approval; actions of regulatory companies, which can have an effect on the initiation, timing and progress of scientific trials and advertising and marketing approval; BeiGene’s skill to realize business success for its marketed medicines and drug candidates, if permitted; BeiGene’s skill to acquire and preserve safety of mental property for its medicines and know-how; BeiGene’s reliance on third events to conduct drug improvement, manufacturing and different providers; BeiGene’s restricted expertise in acquiring regulatory approvals and commercializing pharmaceutical merchandise and its skill to acquire extra funding for operations and to finish the event and commercialization of its drug candidates and obtain and preserve profitability; and the influence of the COVID-19 pandemic on BeiGene’s scientific improvement, regulatory, business and different operations, in addition to these dangers extra absolutely mentioned within the part entitled “Danger Elements” in BeiGene’s most up-to-date quarterly report on Type 10-Q, in addition to discussions of potential dangers, uncertainties, and different essential elements in BeiGene’s subsequent filings with the U.S. Securities and Change Fee. All data on this press launch is as of the date of this press launch, and BeiGene undertakes no obligation to replace such data until required by legislation.

View supply model on


BeiGene Buyers
Gabrielle Zhou
+86 010 5895 8058 or +1 857-302-5189
[email protected]

BeiGene Media
Liza Heapes
+1 857-302-5663
[email protected]

Related posts